Korean Drug
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Korean Drug makes over-the-counter medicines, including a well-known cold remedy called Haben, as well as prescription drugs targeting central nervous system conditions such as epilepsy, stroke, and Parkinson's disease.
Its products reach patients through pharmacies and hospitals across South Korea. Listed on KOSDAQ, the company's core revenue driver is its central nervous system drug line, which it describes as its lead product category, alongside a broader portfolio spanning digestive, dermatological, antibiotic, and vitamin products.
Summary is AI-generated and may contain errors · figures from DART filings
Korean Drug in five facts
What does Korean Drug do?
Korean Drug makes over-the-counter medicines, including a well-known cold remedy called Haben, as well as prescription drugs targeting central nervous system conditions such as epilepsy, stroke, and Parkinson's disease.
Where is Korean Drug listed and in which sector?
Korean Drug (Korean name: 고려제약) trades under KRX code 014570 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Korean Drug?
Its market capitalisation was US$25.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Korean Drug's latest annual revenue and operating profit?
For fiscal year 2025, Korean Drug reported revenue of US$47.2M, operating profit of US$5.2M and net income of US$4.9M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was down 14.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Change of CEOOct 1
- Treasury share disposal: results reportTreasury Shares · May 19
- Material event report (treasury share disposal)
Korean Drug disclosed a plan to sell treasury shares worth US$0.31K, about 0.0% of its market value.
Treasury Shares · May 18 - Treasury share disposal: results reportTreasury Shares · Apr 7
- Material event report (treasury share disposal)
Korean Drug disclosed a plan to sell treasury shares worth US$4.52K, about 0.0% of its market value.
Treasury Shares · Mar 31 - Treasury share disposal: results reportTreasury Shares · Mar 5
- Material event report (treasury share disposal)
Korean Drug disclosed a plan to sell treasury shares worth US$1.15K, about 0.0% of its market value.
Treasury Shares · Mar 3 - Cash/in-kind dividend decision
Korean Drug declared a cash dividend of US$0.12 per share.
Dividend · Feb 24 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Korean Drug reported separate results for FY2025: revenue of US$43.3M (−14.4% year on year), operating profit of US$4.79M (−24.4% year on year) and net income of US$4.52M (+117.4% year on year).
Earnings · Feb 24 - Treasury share disposal: results reportTreasury Shares · Jan 7
- Material event report (treasury share disposal)Treasury Shares · Jan 5